No products in the cart.
Mouse Monoclonal UHRF1 antibody (STJ98567)
Supplier: St John’s Laboratory Ltd.
Recommended applications: WB, IF
Recommended dilution: WB 1:1000-1:2000; IF 1:100-1:500
Recommended protocols: check protocols
Click or hover above images to see image description for UHRF1 Monoclonal Antibody.
Check alternative names for the antibodyExpand
UHRF1 antibody, ICBP90 antibody, NP95 antibody, RNF106 antibody,|Ac2-121 antibody|MGC138707 antibody|NP95 antibody|Nuclear phosphoprotein, 95-KD antibody|Nuclear protein 95 antibody|Nuclear zinc finger protein Np95 antibody|RING finger protein 106 antibody|RNF106 antibody|Transcription factor ICBP90 antibody|Ubiquitin like containing PHD and RING finger domains protein 1 antibody|Ubiquitin like PHD and RING finger domain containing protein 1 antibody|Ubiquitin-like PHD and RING finger domain-containing protein 1 antibody|Ubiquitin-like protein containing PHD and RING finger domains 1 antibody|Ubiquitin-like with PHD and ring finger domains 1 antibody|Ubiquitin-like, containing PHD and RING finger domains, 1 antibody|Ubiquitin-like-containing PHD and RING finger domains protein 1 antibody|UHRF1 antibody|UHRF1_HUMAN antibody|Anti-UHRF1 antibody [EPR18803-11] (ab213223)
SCBT cat No: To be updated
UHRF1 Monoclonal Antibody
|Catalogue No.|| |
UHRF1 Monoclonal Antibody detects endogenous levels of UHRF1 protein.
Purified recombinant human UHRF1 (N-terminus) protein fragments expressed in Ecoli
|Recommended dilution|| |
WB 1:1000-1:2000; IF 1:100-1:500
UHRF1 Antibody was tube-contained. Purified in buffer containing 0.1M Tris-Glycine (pH 7.4, 150 mM NaCl) with 0.2% sodium azide, 50% glycerol.
UHRF1 Antibody was purified using affinity purification.
-20 Celsius degree. Avoid repeated freeze/thaw cycles.
|Alternative antibody names|| |
E3 ubiquitin-protein ligase UHRF1 antibody, Inverted CCAAT box-binding protein of 90 kDa antibody, Nuclear protein 95 antibody, Nuclear zinc finger protein Np95 antibody, HuNp95 antibody, hNp95 antibody, RING finger protein 106 antibody, Transcription factor ICBP90 antibody, Ubiquitin-like PHD and RING finger domain-containing protein 1 antibody, hUHRF1 antibody, Ubiquitin-like-containing PHD and RING finger domains protein 1 antibody
|Protein names|| |
E3 ubiquitin-protein ligase UHRF1 , Inverted CCAAT box-binding protein of 90 kDa , Nuclear protein 95 , Nuclear zinc finger protein Np95 , HuNp95 , hNp95 , RING finger protein 106 , Transcription factor ICBP90 , Ubiquitin-like PHD and RING finger domain-containing protein 1 , hUHRF1 , Ubiquitin-like-containing PHD and RING finger domains protein 1
|Protein function|| |
Multidomain protein that acts as a key epigenetic regulator by bridging DNA methylation and chromatin modification. Specifically recognizes and binds hemimethylated DNA at replication forks via its YDG domain and recruits DNMT1 methyltransferase to ensure faithful propagation of the DNA methylation patterns through DNA replication. In addition to its role in maintenance of DNA methylation, also plays a key role in chromatin modification: through its tudor-like regions and PHD-type zinc fingers, specifically recognizes and binds histone H3 trimethylated at ‘Lys-9’ (H3K9me3) and unmethylated at ‘Arg-2’ (H3R2me0), respectively, and recruits chromatin proteins. Enriched in pericentric heterochromatin where it recruits different chromatin modifiers required for this chromatin replication. Also localizes to euchromatic regions where it negatively regulates transcription possibly by impacting DNA methylation and histone modifications. Has E3 ubiquitin-protein ligase activity by mediating the ubiquitination of target proteins such as histone H3 and PML. It is still unclear how E3 ubiquitin-protein ligase activity is related to its role in chromatin in vivo. May be involved in DNA repair. /
|Protein tissue specificity|| |
Expressed in thymus, bone marrow, testis, lung and heart. Overexpressed in breast cancer.
|Involvement in disease|| |
Note: Defects in UHRF1 may be a cause of cancers. Overexpressed in many different forms of human cancers, including bladder, breast, cervical, colorectal and prostate cancers, as well as pancreatic adenocarcinomas, rhabdomyosarcomas and gliomas. Plays an important role in the correlation of histone modification and gene silencing in cancer progression. Expression is associated with a poor prognosis in patients with various cancers, suggesting that it participates in cancer progression.
|Protein sequence and domain|| |
The tudor-like regions specifically recognize and bind histone H3 unmethylated at ‘Arg-2’ (H3R2me0), while the PHD-type zinc finger specifically recognizes and binds histone H3 trimethylated at ‘Lys-9’ (H3K9me3). The tudor-like regions simultaneously recognizes H3K9me3 through a conserved aromatic cage in the first tudor-like subdomain and unmodified H3K4 (H3K4me0) within a groove between the tandem subdomains (PubMed:21489993, PubMed:21777816 and PubMed:22100450). The linker region plays a role in the formation of a histone H3-binding hole between the reader modules formed by the tudor-like regions and the PHD-type zinc finger by making extended contacts with the tandem tudor-like regions (PubMed:22837395). / The YDG domain (also named SRA domain) specifically recognizes and binds hemimethylated DNA at replication forks (DNA that is only methylated on the mother strand of replicating DNA) (PubMed:17673620). It contains a binding pocket that accommodates the 5-methylcytosine that is flipped out of the duplex DNA. 2 specialized loops reach through the resulting gap in the DNA from both the major and the minor grooves to read the other 3 bases of the CpG duplex. The major groove loop confers both specificity for the CpG dinucleotide and discrimination against methylation of deoxycytidine of the complementary strand (PubMed:18772889). The YDG domain also recognizes and binds 5-hydroxymethylcytosine (5hmC) (PubMed:21731699). / The RING finger is required for ubiquitin ligase activity. / Contains 1 PHD-type zinc finger. / Contains 1 RING-type zinc finger. / Contains 1 ubiquitin-like domain. / Contains 1 YDG domain.
|Protein post-translational modifications|| |
Phosphorylation at Ser-298 of the linker region decreases the binding to H3K9me3. Phosphorylation at Ser-639 by CDK1 during M phase impairs interaction with USP7, preventing deubiquitination and leading to degradation by the proteasome. / Ubiquitinated; which leads to proteasomal degradation. Autoubiquitinated; interaction with USP7 leads to deubiquitination and prevents degradation. Ubiquitination and degradation takes place during M phase, when phosphorylation at Ser-639 prevents intereaction with USP7 and subsequent deubiquitination. Polyubiquitination may be stimulated by DNA damage.
|Protein cellular localization|| |
AntibodyPlus can customize UHRF1 Antibody according to your requirement, including bulk product size,etc. Please contact firstname.lastname@example.org. AntibodyPlus provide antibody trial sample for your own antibody validation and collects antibody reviews.
St John’s Laboratory Ltd.
|Product type|| |
There are no reviews for this product yet.
By submitting a review, get following benefits:
1. Receive $50 ABcoins as credit for each review.
2. First trial sample order will be fully refunded as credit.
3. Have a chance to win a $50 amazon gift card!
There is no extra validation for this product yet.
Check other extra validated antibodies below: